Law360, New York (September 13, 2005, 12:00 AM EDT) -- Drug maker Sanofi-Aventis SA will launch an authorized generic version of the allergy pill Allegra in the U.S. to fight off competition from rival drug makers, which shocked analysts earlier this month with an unusually bold generic launch in the midst of a patent challenge for the $1.4 billion drug.
Sanofi-Avantis said it would launch its so-called “authorized generic” with Prasco Laboratories. The generic drug will be available in 30 mg, 60 mg and 180 mg formulations, the company said.
Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.